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Abstract
Acetyl-DL-leucine is a modified amino acid that was observed to improve ataxic symptoms in patients with sporadic
and hereditary forms of ataxia. Here, we investigated the effect of the treatment with Acetyl-DL-leucine on the walking
stability of patients with cerebellar ataxia (10x SAOA, 2x MSA-C, 2x ADA, 1x CACNA-1A mutation, 2x SCA 2, 1x SCA 1).
Treatment with Acetyl-DL-leucine (500 mg; 3-3-4) significantly improved the coefficient of variation of stride time in 14
out of 18 patients. Moreover, subjective ambulatory scores (FES-I and ABC) and the SARA scores were also improved
under treatment. Further prospective studies are necessary to support these class III observational findings.
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Introduction
Mobility impairments in patients with cerebellar ataxia
(CA) are common. They are associated with a higher
risk of falls, which often result in an increased fear of
falling as well as in serious injuries [1]. Thus, symptom-
atic treatment options for patients with CA should aim
to reduce the occurrence of falls by improving their dy-
namic balance. Gait variability measures which are linked
to dynamic walking stability were found to be associated to
falls in CA [2], thereby providing a novel and also quantita-
tive measure for the assessment of ataxic gait disorders.
Acetyl-DL-leucine, a modified amino acid, was ob-
served to improve ataxic symptoms in patients with
sporadic and hereditary forms of ataxia [3], as well as in
patients with Niemann-Pick Type C [4]. This effect was
not found in a similar study performed in patients with
sporadic, degenerative ataxia only [5].
Here we report on the effect of acetyl-DL-leucine on
temporal gait variability in 18 patients with cerebellar
ataxia (12 sporadic, 6 hereditary ataxia).
Methods
Patients were treated with acetyl-DL-leucine 5 g/d with-
out titration (500 mg tablets of Tanganil™) for at least
4 weeks. Indication for the treatment with acetyl-DL-
leucine were the presence of cerebellar symptoms and
abnormal findings in the domain “gait” of the Scale and
Assessment of Ataxia (SARA). Exclusion criteria were
concomitant diseases that affect locomotion. Twelve out
of the 18 enrolled subjects received physiotherapeutic
treatments with a weekly intensity of 20–60 min already
before the pharmacological off-label treatment and also
during it. Physiotherapy was not started new during the
off-label treatment with acetyl-DL-leucine. All patients
gave their informed consent for the compassionate off-
label use of acetyl-DL-leucine. The series was conducted
by individual treatment efforts of patients after they had
given informed consent. Eight of these patients had been
part of our previous case series [3]. Treatment of pa-
tients took place from 2013 to 2014 at the Department
of Neurology and at the German Center for Vertigo and
Balance Disorders. We performed gait analysis using a
pressure-sensitive carpet (GAITRite®, CIR System,
Havertown, USA; sensor area 6.70 m, sampling rate
120 Hz). The walking pattern of all patients was re-
corded at three different walking speeds (slow, preferred,
and maximal fast). Each speed was tested four times.
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Gait velocity and temporal gait variability quantified by
the coefficient of variation (CV) of stride time were ana-
lyzed. The tests were performed before starting of treat-
ment and during treatment at time point 1 (7–14 days)
and time point 2 (28–42 day). A repeated measure
ANOVA (rmANOVA) with the covariate “walking
speed” and the inner-subject factor “time point” was per-
formed. A Sheffé posthoc analysis was performed.
Results
Clinical examination of patients revealed a moderate se-
verity of symptoms (Scale for Assessment and Rating of
Ataxia (SARA) [6]) and significant gait impairments
(Functional Gait Assessment (FGA) [7] (Table 1).
Compared to the baseline measurement, walking
speed was not significantly different under treatment
at 1-2 weeks or at >4 weeks of treatment. For CV of
stride time, we found a significant reduction in the
rmANOVA model (df = 2, F = 6.64, p < .01), in the
posthoc analysis only for the condition of slow walking
(F = .3.41, p < .05). Here, 14 patients showed a reduc-
tion of CV of stride time by 36 % during 1-2 weeks of
treatment (1-2 weeks) and 49 % during > 4 weeks of
treatment (Fig. 1).
Subjective ambulatory scores (FES-I and ABC) were
also improved in 12 patients, all of which showed a re-
duction of temporal gait variability. The SARA score
showed an improvement of the median from 13 to 11
points (F = 3.25, p < .05) (for further information see
Table 2). This effect did not correlate with the change of
the CV of stride time.
Discussion
In summary, Acetyl-DL-leucine reduced temporal gait
variability in 14 out of 18 patients with sporadic or her-
editary CA. Acetyl-DL-leucine may thus offer a new and
complementary symptomatic treatment option for cere-
bellar gait disorders.
The improvement of variability was restricted to the
condition of slow walking, where walking stability is
thought to critically rely on the sensory integration func-
tion of the cerebellum [8, 9]. In this context it is import-
ant to note that instabilities at slow walking are highly
associated with a history of falls in patients with CA [2].
In animal models, Acetyl-DL-leucine has been shown to
interact with structures of central vestibular function
[10, 11]. An FDG-PET-study in humans demonstrated
increased glucose metabolism in responders to Acetyl-
DL-leucine treatment in central sensorimotor integra-
tion centers [12]. Thereby it may indirectly influence
sensory processing of the cerebellum for maintaining
dynamic stability during walking. We did not find a cor-
relation of gait variability improvement with the im-
provement of clinical scores (FGA, SARA), although the
SARA score did show a significant improvement under
treatment. Taking together the present findings and a re-
cent study on the improvement of gait variability under
treatment with 4-aminopyridine [13, 14], support the
idea that specific functions of walking might be
Table 1 Clinical characteristics and ambulatory functions of the
patients
Demographic characteristics
N 18 (9 women)
mean age (years) 58.83 ± 12.0
height (m) 1.73 ± 0.07
weight (kg) 72.6 ± 6.1
duration of symptoms (months) 72.0 ± 29.3
median SARA score [range] 12 [8; 20]
Etiology of ataxia
sporadic 10x SAOA, 2x MSA-C
hereditary 2x ADA, 1 x CACNA-1A mutation,
2x SCA 2, 1x SCA 1
Walking performance
median FGA score [range] 19 [6; 30]
Ambulatory status
independent 12
Intermediate use of aides 4
prevalent use of aides 2
Legend: Abbreviations: FGA Functional Gait Assessment [7], SARA Scale for the
Assessment and Rating of Ataxia [6], SAOA Sporadic Adult Onset Cerebellar
Atrophy, ADA Autosomal Dominant Ataxia, CACNA-1A Calcium Channel.
voltage-dependent Alpha 1A subunit (P/Q type), SCA Spino Cerebellar
Ataxia MSA-C multiple system atrophy with cerebellar features
Fig. 1 Percent change of the coefficient of variation (CV) of stride
time under continuous treatment with Acetyl-DL-leucine. Legend:
Scatter plot with individual courses of temporal gait variability before
and under treatment with Acetyl-DL-leucine.14 patients showed a
reduction of CV of stride time by 36 % during 1-2 weeks of treatment
(1-2 weeks) and 49 % during > 4 weeks of treatment
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influenced by pharmacotherapy. These findings promote
future randomized placebo-controlled, double-blinded
clinical trials on the symptomatic treatment of CA, such
as the FACEG (Fampridine) and the ALCAT trial
(Acetyl-DL-leucine).
Analysis of speed-dependent effects on gait variabil-
ity showed that non-preferred slow (acetyl-DL-leu-
cine) and fast (4-aminopyridine) walking speeds are
most responsive to pharmacological treatment in pa-
tients with CA. Whereas aminopyridines have been
shown to improve gait variability mainly during fast
walking [13, 14], Acetyl-DL-leucine was effective in
reducing gait variability during slow walking. These
findings are in accordance to an earlier study of our
group showing the amount of gait variability being
highest during slow and fast walking modes [8]. Thus,
future randomized, controlled trials should take the
speed-dependency of gait variability in patients with
CA in account. Moreover, it appears to be questionable
whether the clinical assessment of gait performance as de-
termined in the SARA is sufficient and sensitive enough
to assess improvements of dynamic stability in patients
with CA during therapeutic interventions, since slow
walking modes are commonly not examined.
If considering the assessment of dynamic stability dur-
ing walking, study protocols should also include pro-
spective recording of falls and the examination of gait
variability markers.
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Table 2 Patient characteristics, categorized by patient number, gender, age, etiology, duration of disease, neuro-ophthalmological
findings, participation in a previous case study [3] as well a clinical outcome scores before and under treatment with Acetyl-DL-leucine
ID Age ataxia
type





gender Strupp et al. 2013 [3]
1 73, m SAOA >24 8 12.5 9.5
2 57, w ADA >120 1, 3 8.0 6.0 X
3 73, w SAOA 24 1, 2, 4 20.0 15.0
4 54, w MSA-C 36 1, 2, 5, 8 13.0 12.0
5 59, m SCA 2 56 1, 2, 7, slow saccades 16.0 12.5
6 23, m SCA 2 36 1, 2, 7, slow saccades 13.0 9.0 X
7 68, w ADA >120 1, 2, 3, 6, 7, 8, hypometric saccades 17.0 11,0 X
8 60, m SAOA 24 1, 6 14.0 12.5 X
9 68, w MSA-C 36 1, 2 10,0 9.5
10 54, m SAOA 60 1, 2, 6, 8 12.0 9.5
11 63, w SAOA >120 1, 2, 3, 4, 6, 7 14.5 12.5 X
12 51, m SAOA 36 1, 2, 3, 6, 7 hypometric saccades 14.0 12.0 X
13 51, w EA 2 24 1 17.0 16.0
14 49, m SAOA 36 1, 2, 6, 7 16.5 15.5
15 63, w SAOA >120 1, 2, 3, 4, 6, 7 11.5 7.0 X
16 67, m SAOA 48 1, 2, 4 13.5 11.5
17 60, m SAOA 36 1, 3, 5, 8 16.0 12.5
18 47, w SCA 1 36 1, 2, 5 (bilateral), 6, 7, hypermetric saccades 17.0 9.5 X
Legend: Abbrevations: m man, w woman, SCA spino cerebellar ataxia, EA 2 episodic ataxia type 2, MSA-C multiple system atrophy with cerebellar features, SAOA
sporadic adult-onset ataxia of unknown etiology, ADA autosomal dominant cerebellar ataxia, 1 saccadic smooth pursuit, 2 gaze-evoked nystagmus, 3 head-
shaking nystagmus, 4 rebound nystagmus, 5 pathological head-thrust test (uni- or bilateral), 6 impaired visual fixation suppression of the VOR, 7 pathological
optokinetic reflex, 8 downbeat nystagmus
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